CVR number 37507075
Industry 46.4610 Wholesale of pharmaceutical goods

Kørestolseksperten ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  1.1% 1.1% 1.1% 1.1% 1.1%  
Bankruptcy risk  6.9% 6.2% 4.2% 2.1% 2.3%  
Credit score (0-100)  36 38 47 67 64  
Credit rating  BBB BBB BBB A BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.3 0.1  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  1,007 1,182 1,808 2,310 2,163  
EBITDA  429 702 1,194 1,265 554  
EBIT  429 702 1,194 1,249 514  
Pre-tax profit (PTP)  421.0 695.9 1,193.8 1,289.2 543.2  
Net earnings  326.8 542.0 926.8 1,003.2 420.0  
Pre-tax profit without non-rec. items  421 696 1,194 1,289 543  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  0.0 0.0 0.0 140 132  
Shareholders equity total  397 839 1,566 2,369 2,489  
Interest-bearing liabilities  135 106 81.3 278 567  
Balance sheet total (assets)  1,000 1,690 2,595 3,789 4,392  
Net Debt  -61.5 -522 -678 -876 2.1  
 
See the entire balance sheet

Volume 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  1,007 1,182 1,808 2,310 2,163  
Gross profit growth  68.6% 17.4% 53.0% 27.7% -6.4%  
Employees  2 2 2 3 4  
Employee growth %  0.0% 0.0% 0.0% 50.0% 33.3%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,000 1,690 2,595 3,789 4,392  
Balance sheet change%  21.4% 69.0% 53.6% 46.0% 15.9%  
Added value  429.3 701.9 1,194.4 1,249.3 554.1  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 124 -47  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  3.0 4.0 5.0 5.0 5.0  

Profitability 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  42.7% 59.4% 66.1% 54.1% 23.8%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  47.1% 52.2% 56.1% 41.0% 13.9%  
ROI %  121.4% 95.1% 92.8% 60.8% 19.9%  
ROE %  115.3% 87.7% 77.1% 51.0% 17.3%  

Solidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  39.7% 49.6% 60.3% 62.5% 56.7%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -14.3% -74.3% -56.8% -69.3% 0.4%  
Gearing %  34.0% 12.6% 5.2% 11.8% 22.8%  
Net interest  0 0 0 0 0  
Financing costs %  11.8% 5.0% 8.8% 10.4% 6.2%  

Liquidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  0.6 1.1 1.5 1.9 1.8  
Current Ratio  1.7 2.0 2.3 2.4 2.1  
Cash and cash equivalent  196.6 627.8 759.3 1,154.6 565.1  

Capital use efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  396.8 838.8 1,325.7 1,994.3 2,121.5  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  215 351 597 416 139  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  215 351 597 422 139  
EBIT / employee  215 351 597 416 129  
Net earnings / employee  163 271 463 334 105